Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.67 |
| ▸ | FLT1 | P17948 | 1/20 | 0.67 |
| ▸ | FLT4 | P35916 | 1/20 | 0.67 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | KIF5B | P33176 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 14/20 | 0.47 |
| ▸ | RAF1 | P04049 | 6/20 | 0.47 |
| ▸ | KDM1A | O60341 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12456408 | 0.87 | KDR (0.52) | KDRFLT1FLT4RETKIF5B | |
| Fruquintinib SCHEMBL947183 | 0.80 | KDR (1.00) | KDRFLT1FLT4RETKIF5B | |
| Fruquintinib SCHEMBL29366206 | 0.80 | KDR (1.00) | KDRFLT1FLT4RETKIF5B | |
| SCHEMBL945652 | 0.80 | KDR (0.68) | KDRFLT1FLT4RETKIF5B | |
| Fruquintinib SCHEMBL29516397 | 0.80 | KDR (1.00) | KDRFLT1FLT4RETKIF5B | |
| SCHEMBL11931692 | 0.79 | KDR (0.66) | KDRFLT1FLT4RETKIF5B | |
| SCHEMBL12909830 | 0.74 | KDR (0.87) | KDRFLT1FLT4BRAFRAF1 | |
| SCHEMBL30415453 | 0.73 | KDR (0.72) | KDRFLT1FLT4RETKIF5B | |
| SCHEMBL945594 | 0.72 | KDR (0.83) | KDRFLT1FLT4BRAFRAF1 | |
| SCHEMBL11931698 | 0.71 | KDR (0.83) | KDRFLT1FLT4BRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497372-B2 | Use of substituted quinazoline compounds in treating age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-07-30 | — | — | US | disclosed |
| US-8212033-B2 | Use of substituted quinazoline compounds in treating angiogenesis-related diseases | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2012-07-03 | — | — | US | disclosed |
| US-8212033-B2 | Use of substituted quinazoline compounds in treating angiogenesis-related diseases | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2012-07-03 | — | — | US | disclosed |
| US-20110015213-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERRISES LIMITED | 2011-01-20 | — | — | US | disclosed |
| US-20110015213-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERRISES LIMITED | 2011-01-20 | — | — | US | disclosed |
| WO-2009137797-A2 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015213-A1 | QUINAZOLINE DERIVATIVES | FLT4, FLT1, ARG1 | KDR 4/4885FLT1 2/4885FLT4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.